RxDoctor Payments Data

Timothy Graham, MD

Endocrinology, Diabetes & Metabolism · Sandy, UTNPI 1134162258

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $64,768 of the $90,342 with a category attached, or 71.7%. 54 manufacturers reported payments, led by Novo Nordisk at 51.4% of the total. Reporting peaked in 2019 at $34,338 and has fallen 51.4% since, to $16,687 in 2025.

$90,342in general payments, 2019–2025

Across 588 payments — averaging $153.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$46K
  • Sanofi$12K
  • Tandem Diabetes Care, Inc.$11K
  • Sanofi-aventis U.S. LLC$6K
  • Ascendis Pharma Endocrinology Inc$5K
  • Insulet Corporation$2K
  • plus $9K from 48 others
$499,754in research payments, 2019–2025

Across 280 payments — averaging $1784.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sequel Med Tech, LLC$205K
  • Eli Lilly$113K
  • Tandem Diabetes Care, Inc.$99K
  • Novartis$42K
  • Ascendis Pharma Endocrinology Inc$32K
  • Sanofi US Services Inc.$10K

What the payments were for

  • Consulting fees$10,92912%
  • Speaking & faculty fees$64,76872%
  • Travel & lodging$4,0214%
  • Food & beverage$9,99411%
  • Education$5911%
  • Entertainment$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,342 in reported general payments places this provider in the 85th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.

See all endocrinology, diabetes & metabolism providers in Utah

Medicare billing

Part B allowed, 2024
$143,094
Medicare patients
381
Services billed
2,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide204$254,960
OzempicSemaglutide141$201,720
Soliqua 100-33Insulin Glargine/Lixisenatide146$200,697
SamscaTolvaptan12$175,345
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog106$151,284
TrulicityDulaglutide83$119,023
JardianceEmpagliflozin96$115,781
FarxigaDapagliflozin Propanediol99$93,447
Somatuline DepotLanreotide Acetate11$91,134
ForteoTeriparatide12$59,779
Tresiba Flextouch U-200Insulin Degludec35$58,947
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog40$54,306
Xigduo XrDapaglifloz Propaned/Metformin44$49,754
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/731$41,449
KerendiaFinerenone34$40,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Insulin Lispro$557$446,519354 claims
Novo NordiskOzempic, Novolog$46,458$210,120166 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$5,618$200,697146 claims
Boehringer IngelheimJardiance, Synjardy Xr$205$151,754127 claims
AstraZenecaFarxiga$253$93,44799 claims
BayerKerendia$67$40,30934 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$5,415468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.

Other endocrinology, diabetes & metabolism in Sandy

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →